rologie i - European Congress of Virology

5 th European Congress of Virologytransmission to immune compromised patients who may experienceserious clinical consequences. We aimed to establish the added valueof detecting HEV by PCR compared to IgM and IgG serology in a lowrisk general population and a selected hospital patient group with suspicionof viral hepatitis in Amsterdam and surroundings, the Netherlands.At the Public Health Laboratory, Amsterdam a real time Taqman PCRtargeting the Orf3A region of HEV was validated. A panel with knownHEV genotypes was used to establish the sensitivity and specificity. Storedplasma samples (n=90), collected in 2004 among the general population inAmsterdam were used. Serum samples (n=30) collected in 2012 from differentoutpatient clinics and hospital wards from patients with complaintsrelated to viral hepatitis were tested by PCR and for IgM and IgG HEVantibodies (Wantai kit). Nucleic acids were isolated from plasma using aTriPure kit (Roche diagnostics). PhHV was used as internal control in thereal time PCR.The HEV PCR targeting the orf3A region had a sensitivity of 83% and100% specificity relative to the validation panel and could detect at leastgenotypes 1 and 3. When applied to the 90 plasma samples none werepositive in the HEV PCR. However, 44 samples were HEV IgG positive,and one was also HEV IgM positive. A HEV IgG prevalence of around 50%was thus noted and even when considering that we used a biased sampleselection, the HEV prevalence was much higher than among healthy blooddonors in the Netherlands (27%). Testing the sera of the 30 non ABChepatitis patients showed one positive HEV PCR result. This sample wasfrom a 65 year old male who was seen with hepatitis like complaints. Hewas also IgM and IgG positive, indicating a recent infection. An additional5 sera (from 3 males and 2 females) were both IgG and IgM positive. Theadded value of performing HEV PCR would thus have been very low forthese hospital patients. We conclude that in non travel related hepatitispatients the serology for HEV suffices to establish HEV as a cause. HEVPCR may remain of added value in suspected cases of acute hepatitis andin immune compromised persons.REF 371The results of the implementation epidemiological surveillance systemand control and response measures to influenza, acute viral respiratoryinfections (ARI) and severe acute respiratory infection (SARI)Spinu CONSTANTIN, Scoferta PETRU, Cojocaru RADU, EderVERONICA, Spinu IGOR, Gostev IGOR, Gheorghita STELANational Center for Public Health, Chisinau, REPUBLIC OF MOLDOVAThe health system of the Republic of Moldova has a nominated infectionssurveillance system, developed with the support of the World Bankand adjusted to the requirements of WHO, ECDC and CDC, which isconnected to the European network EuroFlu and global FluNet WHOinfluenza surveillance, ARI and SARI. This system includes the NationalInfluenza Center accredited by WHO, a biosafety level BSL 2 and BSL 2+,with modern equipment, supplies and qualified personnel able to performthe techniques of classical virology and molecular biology. Exploring theepidemiological surveillance system for influenza during 2012 (week 40)2013 (week 12) made it possible to highlight: extensive spreading, mediumintensity 12,770/0000, apogee at week 08/2013, the trend of increas anddiscreas respectively 2.8 0/0000 and 2,24 0/0000 Influenza morbidity wasincluded within weeks 04/2013 12/2013, identified viruses: A (H1N1)pdm, A (H3N2) and B dominant strain A (H1N1)pdm (51.44%), the rate ofpositive samples during apogee, increas and discreas, was 48.8%, 58.5%and 47.7% respectively, were mostly affected person aged 15 64 years(63.2%) and children 0 14 years (32.0%). Categories of pregnant womenand patients with immunocompromised status with confirmed influenzawere 22, 1% and 22.5%, respectively. ARI morbidity in apogee periodwas 468,60/0000 and reached epidemic threshold 189,70/0000 and bySARI – 76,6 0/0000 increased compared to the same period of last season– 48,30/0000. Control and response measures: making epidemiologicalsurveillance based on specific and nonspecific indicators allowed to vaccinateabout 100 000 at risk population, predict in real time the evolutionof influenza morbidity, health system impact assessment, then appreciatedas moderate, confirm clinical biodiagnostical influenza, arguing the needfor initiation of therapy avoid severe postinfluenza complications, appreciatingthat Oseltamivir and Zanamivir sensitive influenza virus strainsidentified, demonstrating isolated strains belonging and place global phylogenetictree and argue the need to extend the at risk population forimmunization with vaccine recommended by WHO for the season 20132014.REF 372Active cytomegalovirus infection among patients in the clinics of theUniversity of Szeged between 2008 and 2012Judit DEÁK 1 , Laura Elizabeth BROWN 1,2 , Judit NÉMETH 1,2 , RozáliaPUSZTAI 21 Institute of Clinical Microbiology, Faculty of Medicine, University ofSzeged, Szeged, HUNGARY; 2 Department of Medical Microbiology andImmunobiology, Faculty of Medicine, University of Szeged, Szeged, HUN-GARYThe incidence of active cytomegalovirus (CMV) infection was determinedamong patients in the clinics of the University of Szeged, Hungaryfrom January 2008 to December 2012. This study included all consecutivepatients who were examined for active CMV infection. Duringthe 5 year period 2151 samples (EDTA/blood, urine or liquor) from 994patients (485 male, 509 female) were investigated. CMV load was monitoredby real time quantitative PCR (Roche). IgM and IgG antibodiesspecific for CMV were tested in sera by ELISA (Sorin). CMV activeinfection occurred in 135 (13.6%) patients ranging from 0 days to 75years old (mean age 34 years). Twenty four, 15, 39, and 22% of themwere in age groups 60 years, respectively. Theactive CMV infections were linked to malignant disease (36%), congenital/perinatalinfection (20%), renal disease (14%), and other diseases(30%), such as neurological disorder (7 cases), autoimmune disease (5cases), etc. Antiviral treatment (ganciclovir, valganciclovir or acyclovir)was initiated in 75 (55.6%) patients and CMV load was monitored. Theantiviral treatment was effective in 50 patients (66.6%). In conclusion, theincidence of active CMV infection is substantial among patients with malignantdisease, congenital infection, and renal disease and may affect theoutcome of disease. More extensive studies of statistical impact investigatingactive CMV infection, especially in patients with malignant disease,are necessary. The impact of antiviral agents on clinically meaningfuloutcomes in these patients should be determined.REF 373Viral hepatitis C in hemodialysisMohamed EL AMRANI 1 , Mohamed Amine HAMZI 1 , WafaeARRACHE 1 , Driss KABBAJ 1 , Taoufik DOBLALI 2 , BouchraBELFQUIH 2 , Mohammed Reda TAGAJDID 2 , Hicham EL ANAZ 2 ,Nadia TOUIL 2 , Saad MRANI 2 , Mohammed BENYAHIA 11 Department of nephrology, dialysis and renal transplantation, Rabat,MOROCCO; 2 Department of human and molecular virology, Rabat,MOROCCOBackground: Hepatitis C virus (HCV) infection is the first hepatitis etiologyin chronic hemodialysis. Our objective is to define the anti HCVantibody prevalence, the seroconversion rate and the main HCV infectionrisk factors in hemodialysis patients in the military teaching hospitalMohammed V. Patients and methods: ambispective study concerning141 hemodialysis patients, between April 2010 and September 2012.HCV serology and PCR were both performed. Results: the mean age was52.6 years with a male predominance. The median hemodialysis durationwas 43.0 months. Predominant initial nephropathy was diabetes (25.5%).Virologie, Vol 17, supplément 2, septembre 2013S223